KALA BIO, Inc. (KALA)
KALA BIO, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Arlington, MA, US. The stock last traded at $0.90, up 6.91% on the session, giving a market capitalisation of $17.5M. On trailing twelve-month figures it carries a trailing P/E of -0.31, a net margin of 0.0%. Its beta of -2.28 implies it has historically moved less than the broad market.
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
KALA BIO, Inc. is most often compared with the following Healthcare names: